Matinas BioPharma Holdings (MTNB) Change in Account Payables (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Change in Account Payables of $397000.0 for Q1 2026, up 112.3% year-over-year from $187000.0 in Q1 2025, and up 68.94% quarter-over-quarter from $235000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Change in Account Payables (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Change in Account Payables for 14 consecutive years, with $397000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 112.3% year-over-year to $397000.0; the TTM figure through Mar 2026 stood at $430000.0 (up 325.13% YoY), while the FY2025 annual figure was $220000.0, up 152.51% from the prior year.
- Change in Account Payables rose to $397000.0 in Q1 2026 per MTNB's latest filing, from $235000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $414000.0 in Q1 2022 and bottomed at -$855000.0 in Q2 2022.
- Historically, Change in Account Payables has averaged -$13294.1 across 5 years, with a median of -$39000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Account Payables sank 3067.1% — and 2025, when it jumped 556.1%.
- Matinas BioPharma Holdings' Change in Account Payables stood at -$39000.0 in 2022, then slumped by 720.51% to -$320000.0 in 2023, then gained by 20.62% to -$254000.0 in 2024, then soared by 192.52% to $235000.0 in 2025, then surged by 68.94% to $397000.0 in 2026.
- Business Quant data shows MTNB's Change in Account Payables at $397000.0 in Q1 2026, $235000.0 in Q4 2025, and -$86000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | 132,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 132,000.00 |
| Jun 30, 2026 | 132,000.00 |
| Mar 31, 2026 | 397,000.00 |
| Mar 31, 2026 | 397,000.00 |
| Dec 31, 2025 | 235,000.00 |
| Dec 31, 2025 | 235,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Jun 30, 2025 | -116,000.00 |
| Jun 30, 2025 | -116,000.00 |
| Mar 31, 2025 | 187,000.00 |
| Mar 31, 2025 | 187,000.00 |
| Dec 31, 2024 | -254,000.00 |
| Dec 31, 2024 | -254,000.00 |
| Sep 30, 2024 | 111,000.00 |
| Sep 30, 2024 | 111,000.00 |
| Jun 30, 2024 | -235,000.00 |
| Jun 30, 2024 | -235,000.00 |
| Mar 31, 2024 | -41,000.00 |
| Mar 31, 2024 | -41,000.00 |